# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Leonard Nimoy (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML017-SYN
- Date: 2026-05-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carla Benedetti, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month COPD review after pulmonary rehabilitation. **S**

## History of present illness

Mr. Nimoy returns three months after starting tiotropium-olodaterol and four days after finishing pulmonary rehabilitation. He attended all 24 sessions. He now walks about 300 meters at his own pace before stopping, uses the pursed-lip breathing he learned there, and has a home program of walking twice a day and strength exercises three times a week. He uses albuterol about twice a week, mostly before longer walks. He has taken every maintenance dose. He has had no flare-up, antibiotic or prednisone course, or emergency visit. He repeated the 6-minute walk in the pulmonary function laboratory this morning. The pneumococcal vaccine that was out of stock at the last visit is available today. **S**

| Element | Detail |
|---|---|
| Rehabilitation | Completed 24 of 24 sessions four days ago; home program in place |
| Exercise tolerance | Walks about 300 meters before stopping |
| Reliever use | Albuterol about twice a week |
| Adherence | All maintenance doses taken |
| Exacerbations | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless after about 300 meters or a flight of stairs; no increase in cough or sputum |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Musculoskeletal | Negative | No injuries or joint pain from the exercise program |

3 systems reviewed. **S**

## Current medications

- Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) **S**
- Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/76 mmHg; pulse 78 bpm; respirations 18/min; temperature 36.7 °C; oxygen saturation 94% on room air; weight 80.8 kg; BMI 23.6 kg/m². All vital signs are synthetic.

6-minute walk distance: 330 m (low). All results are synthetic.

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Comfortable at rest; speaks in full sentences |
| Lungs | Reduced breath sounds with prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm at 78 per minute; no edema |
| Inhaler technique | Correct with his soft mist inhaler |

All examination findings are synthetic. **S**

## Assessment and plan

1. **COPD, GOLD 3, group B, improved after rehabilitation** (J44.9). CAT 15, down from 22 at intake; mMRC grade 2, down from 3. 6-minute walk 330 m, 60 m farther than at rehabilitation entry, with a lowest saturation of 90 percent. Resting saturation 94 percent. Still group B, with no exacerbations. **S**
   - Continue tiotropium-olodaterol and albuterol as needed.
   - Keep up the home exercise program; a maintenance exercise class was offered.
   - PCV20 given today.
   - Spirometry again at the yearly review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | COPD Assessment Test (CAT) | Every visit | Completed today | 15, down from 19 at four weeks and 22 at intake |
| Survey | mMRC dyspnea grade | Every visit | Completed today | Grade 2, down from 3 |
| Survey | Exacerbation history and GOLD group | Every visit | Completed today | None; group B |
| Examination | Pulse oximetry | Every visit | Completed today | 94 percent at rest on room air |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco |
| Examination | BMI and nutritional status | Every visit | Completed today | BMI 23.6; weight up 0.6 kg with exercise |
| Examination | Inhaler technique and adherence | Every visit | Completed today | Correct; full adherence |
| Examination | 6-minute walk test | At pulmonary rehabilitation entry and exit, and for oxygen assessment | Completed today | 330 m at rehabilitation exit, up 60 m; lowest saturation 90 percent |
| Examination | Long-term oxygen assessment | As indicated: resting saturation 88 percent or less, confirmed twice at least three weeks apart | Not indicated | Resting saturation 94 percent; no oxygen criterion met |
| Referral | Pulmonary rehabilitation | Stable mMRC 2 or more or CAT 10 or more; within three weeks of any hospital stay for an exacerbation | Completed today | Program completed four days ago, 24 of 24 sessions; home program and maintenance class offered |
| Examination | Spirometry | At diagnosis, then at least yearly and with significant clinical change | Up to date | Next in nine months, at the yearly review |
| Laboratory | Blood eosinophil count | At baseline and when an inhaled corticosteroid is considered | Not indicated | No change in inhaled corticosteroid being considered |
| Medication safety | Vaccination status | Reviewed yearly | Completed today | PCV20 given today, nine weeks later than planned. Deviation: the dose planned at the four-week visit was missed because the vaccine was out of stock. No harm resulted: he had no respiratory infection in the interval. Corrective action: vaccine stock is checked before a planned dose is booked, and missed doses are added to the next visit's orders |

## Goal progress

- CAT score at least 2 points lower by the three-month review. Outcome by 2026-05-12: CAT fell from 22 to 15. **S**
- 6-minute walk distance at least 30 meters farther after pulmonary rehabilitation. Outcome by 2026-05-12: 270 m at entry and 330 m at exit. **S**
- No moderate or severe exacerbation over the six months after starting maintenance therapy. In progress; target 2026-08-11. **S**
- Correct soft mist inhaler technique and a daily maintenance dose. Outcome by 2026-03-10: Correct technique on demonstration and no missed doses by dose counter at four weeks. **S**

## Guideline basis

- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025), Global Initiative for Chronic Obstructive Lung Disease
- CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026), Aether Forge
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (Am J Respir Crit Care Med 2023;208(4):e7-e26)
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (Am J Respir Crit Care Med 2020;202(10):e121-e141)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- COPD review in three months, or the same day for any flare-up. **S**
- Next scheduled visit 2026-08-11: six-month COPD review. **S**
